Tome Biosciences
Watertown, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $213M
Overview
Engineers precise large-scale DNA integration for next-generation gene and cell therapies.
Genetic DiseasesOncologyAutoimmune Diseases
Technology Platform
A novel gene editing platform designed for the precise, targeted integration of large DNA sequences into any specified location in the genome.
Funding History
1Total raised:$213M
Venture$213M
Opportunities
Potential to unlock a new class of genetic medicines that require precise, multi-gene integration, addressing a wide range of complex diseases.
Risk Factors
High technical risk of developing a novel, unproven editing platform and navigating the complex safety and delivery challenges of in-vivo gene integration.
Competitive Landscape
Seeks to compete with established CRISPR companies by offering a potentially superior tool for large DNA insertions, a key bottleneck in advanced gene therapy.